AstraZeneca expects US vaccine data ‘soon’ — with 50M doses ready by the end of April
AstraZeneca said it’s readying the release of data from its US-based Phase III trial, which has more than 32,000 participants, for its upcoming emergency use …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
